.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,265,228

« Back to Dashboard

Details for Patent: 7,265,228

Title:Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Inventor(s): Hirth; Bradford H. (Littleton, MA), Siegel; Craig (Woburn, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Filing Date:Aug 12, 2004
Application Number:10/916,824
Claims:1. A method of preparing a sphingosine-like compound represented by the following structural formula: ##STR00033## said method comprising the step of debenzylating the --NHCH(--CH.sub.2OH)R.sub.5 group of an amine compound represented by the following structural formula: ##STR00034## wherein: R.sub.1 is a substituted or unsubstituted aromatic group; R.sub.2 and R.sub.3 are independently --H, a substituted or unsubstituted aliphatic group or, taken together with the nitrogen atom to which they are bonded, are a substituted or unsubstituted non-aromatic heterocyclic ring; and R.sub.5 is a substituted or unsubstituted aromatic group.

2. The method of claim 1 wherein the amine compound is debenzylated by hydrogenation.

3. The method of claim 2 wherein the amine compound is debenzylated by hydrogenation under a hydrogen atmosphere with a catalytic amount of Pd(OH).sub.2.

4. The method of claim 1 further comprising the step of acylating the primary amine group of the sphingosine-like compound, thereby forming a ceramide-like compound represented by the following structural formula: ##STR00035## wherein R.sub.7 is a C1-C30 straight chained alkyl or alkenyl group.

5. The method of claim 4 wherein the sphingosine-like compound is acylated with R.sub.7COX, wherein is X is --Cl or N-hydroxysuccinimidyl.

6. The method of claim 1, wherein the sphingosine-like compound has an enantiomeric excess of at least 10%.

7. The method of claim 1, wherein the sphingosine-like compound has an enantiomeric excess of at least 90%.

8. The method of claim 1, wherein the sphingosine-like compound has an enantiomeric excess of at least 98%.

9. The method of claim 1, wherein R2 and R3 taken together with the nitrogen atom to which they are bound are pyrrolidinyl.

10. The method of claim 9, wherein R5 is a substituted or unsubstituted phenyl group.

11. The method of claim 10, wherein R1 is a phenyl group substituted in the meta/para positions with --OCH.sub.2O--, --OCH.sub.2CH.sub.2O-- or in the para position with halo, lower alkyl thiol, --OH, --O(phenyl), --OCH.sub.2(phenyl), lower alkyl, amino, lower alkyl amino, lower dialkyl amino, or --O(lower alkyl).

12. The method of claim 10, wherein R1 is a phenyl group substituted in the meta/para positions with --OCH.sub.2O-- or --OCH.sub.2CH.sub.2O--.

13. The method of claim 10, wherein R1 is a phenyl group substituted in the meta/para positions with --OCH.sub.2CH.sub.2O--.

14. The method of claim 5, wherein R1 is a phenyl substituted in the mela/para positions with --OCH.sub.2O-- or --OCH.sub.2CH.sub.2O-- or in the para position with halo, CH.sub.3O--, CH.sub.3CH.sub.2O--, CH.sub.3CH.sub.2CH.sub.2O--, CH.sub.3(CH.sub.3)CHO--, CH.sub.3--, CH.sub.3CH.sub.2--, CH.sub.3CH.sub.2CH.sub.2--, CH.sub.3(CH.sub.3)CH--, --OH or --OCH.sub.2(phenyl); and R.sub.7 is CH.sub.3(CH.sub.2).sub.n-or CH.sub.3(CH.sub.2).sub.n-2CH.dbd.CH--, wherein n is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.

15. The method of claim 14, wherein n of R7 is 7 or 8.

16. The method of claim 15, wherein R1 is a phenyl substituted with --OCH.sub.2CH.sub.2O--.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc